Treatment Approaches to Mycobacterium abscessus Pulmonary Disease

MAB-PD presents a significant therapeutic challenge due to the poor treatment outcomes and toxicity of current guidelines-based therapy. Macrolide susceptibility is a key prognostic factor and should be protected by adequate companion drugs during intensive and continuation phases. Optimal drug combinations, duration of therapy, and management of refractory disease are unknown. Fortunately, there are multiple emerging therapeutic candidates to address the unmet need for efficacious and tolerable treatment options.